PropertyValue
?:abstract
  • There is an urgent need to identify therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Although repurposed drugs with favorable safety profiles could have significant benefit, widely available prevention or treatment options for COVID-19 have yet to be identified. Efforts to identify approved drugs with in vitro activity against SARS-CoV-2 resulted in identification of antiviral sigma-1 receptor ligands, including antihistamines in the histamine-1 receptor binding class. We identified antihistamine candidates for repurposing by mining electronic health records of usage in population of more than 219,000 subjects tested for SARS-CoV-2. Usage of diphenhydramine, hydroxyzine and azelastine was associated with reduced incidence of SARS-CoV-2 positivity in subjects greater than age 61. We found diphenhydramine, hydroxyzine and azelastine to exhibit direct antiviral activity against SARS-CoV-2 in vitro. Although mechanisms by which specific antihistamines exert antiviral effects is not clear, hydroxyzine, and possibly azelastine, bind Angiotensin Converting Enzyme-2 (ACE2) and the sigma-1 receptor as off-targets. Clinical studies are needed to measure the effectiveness of diphenhydramine, hydroxyzine and azelastine for disease prevention, for early intervention, or as adjuvant therapy for severe COVID-19.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.bbrc.2020.11.095
?:journal
  • Biochem_Biophys_Res_Commun
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/940a383f6c26f9642cd8c32463392b6ff890c47d.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7713548.xml.json
?:pmcid
?:pmid
?:pmid
  • 33309272.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Identification of antiviral antihistamines for COVID-19 repurposing
?:type
?:year
  • 2020-12-03

Metadata

Anon_0  
expand all